Last reviewed · How we verify
NCT04737837
A Real World Study on the Efficacy and Safety of Lacosamide as Add-on Therapy for Focal-onset Epilepsy
trial testing lacosamide in Epilepsy in 200 participants. Status unknown.
28 November 2021
Quick facts
| Lead sponsor | Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 31 January 2021 |
| Primary completion | 28 November 2021 |
| Estimated completion | 28 February 2022 |
| Sites | 19 locations across China |
Drugs / interventions tested
- lacosamide (lacosamide) — full drug profile →
Conditions studied
- Epilepsy — all drugs for Epilepsy →
- Focal-Onset Seizure — all drugs for Focal-Onset Seizure →
Sponsor
Jiangxi Qingfeng Pharmaceutical Co. Ltd. — full company profile →
Who can join
Adults 4 to 75, any sex, with Epilepsy or Focal-Onset Seizure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this trial is to evaluate the efficacy, safety, and pharmaco-economics of Lacosamide Tablet as first add-on therapy for uncontrolled focal onset epilepsy ,invetigating effects of lacosamide Tablet on cognitive function of children and anxiety and depression of adults with focal onset seizures In real-world clinical setting
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04737837
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of lacosamide
Trials testing the same drug.
- NCT03196466 — Population Pharmacokinetics of Antiepileptic in Pediatrics · completed
- NCT01345058 — Add on Lacosamide Versus High Dose Monotherapy · Phase 3 · completed
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other Jiangxi Qingfeng Pharmaceutical Co. Ltd. trials
Trials by the same sponsor.
- NCT06574503 — Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza · Phase 3 · recruiting
- NCT06573008 — Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications · Phase 3 · recruiting
- NCT06678542 — Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects · Phase 1 · completed
- NCT06643156 — Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension · Phase 1 · completed
- NCT05814926 — GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04737837 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Last refreshed: 4 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04737837.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing